For the roughly 60,000 Americans living with acromegaly, the prospect of replacing lifelong monthly injections with a daily pill represents a meaningful quality-of-life shift. Four-year interim data now offer the longest continuous look yet at whether an oral somatostatin receptor agonist can hold its own against the injectable standard of care — a question with real consequences for adherence and disease management.
The ACROBAT Advance open-label extension enrolled 43 patients who had previously completed either the Edge or Evolve phase 2 trials on injectable somatostatin receptor ligands (SRLs) such as octreotide or lanreotide. Paltusotine — the first non-peptide, selective somatostatin receptor subtype-2 agonist to reach oral formulation — was titrated up to 60 mg daily when a tablet form became available in year three. Across nearly four years of follow-up (week 207), median IGF-I levels normalized from roughly 1.17× the upper limit of normal at extension entry to approximately 1.01× ULN in the 20 patients with data at that timepoint. Growth hormone concentrations, acromegaly symptom burden, and pituitary tumor dimensions remained stable throughout, and no unexpected adverse safety signals emerged.
This dataset is incremental but genuinely meaningful for a rare, chronically managed disease. Oral SRL therapy has long been an aspirational goal in endocrinology; injectables impose clinic visits, injection-site reactions, and patient burden that erode adherence over decades. Paltusotine's selectivity for somatostatin receptor subtype 2 — rather than the broader receptor binding of earlier peptide ligands — theoretically reduces glucose dysregulation risk, an important consideration given acromegaly's association with insulin resistance. Key limitations here are substantial: only 20 of 43 patients had week-207 data, the study is open-label without a comparator arm, and the modest cohort size precludes robust safety signal detection. Eighteen percent of patients discontinued, and the reasons matter enormously for long-term clinical planning. Still, as confirmatory evidence for a first-in-class oral agent, this marks a credible step toward pill-based acromegaly management.